nach oben

Erschienen in:

01.12.2013 | Original Article

Factors Associated with Discontinuation of Bupropion and Counseling Among African American Light Smokers in a Randomized Clinical Trial

verfasst von: Nicole L. Nollen, Ph.D., Matthew S. Mayo, Ph.D., Jasjit S. Ahluwalia, M.D., M.P.H., M.S., Rachel F. Tyndale, Ph.D., Neal L. Benowitz, M.D., Babalola Faseru, M.D., M.P.H., Taneisha S. Buchanan, Ph.D., Lisa Sanderson Cox, Ph.D.

Erschienen in: Annals of Behavioral Medicine | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

African Americans are at risk of inadequate adherence to smoking cessation treatment, yet little is known about what leads to treatment discontinuation.

Purpose

The purpose of this study was to examine the factors associated with discontinuation of treatment in African American light smokers (≤10 cigarettes per day).

Methods

Bupropion plasma levels and counseling attendance were measured among 540 African American light smokers in a placebo-controlled randomized trial of bupropion.

Results

By week 3, 28.0 % of subjects in the bupropion arm had discontinued bupropion, and only moderate associations were found between the plasma levels and self-reported bupropion use (r _s = 0.38). By week 16, 36.9 % of all subjects had discontinued counseling. Males had greater odds of discontinuing medication (OR = 2.02, 95% CI = 1.10–3.71, p = 0.02), and older adults had lower odds of discontinuing counseling (OR = 0.96, 95% CI = 0.94–0.97, p < 0.0001).

Conclusions

Bupropion and smoking cessation counseling are underutilized even when provided within the context of a randomized trial. Future research is needed to examine strategies for improving treatment utilization among African American smokers. Trial Registration No. NCT00666978 (www.clinicaltrials.gov).

Caraballo RS, Yee SL, Gfroerer J, Mirza SA. Adult tobacco use among racial and ethnic groups living in the United States, 2002–2005. Prev Chron Dis. 2008;5:A78.

Trinidad DR, Perez-Stable EJ, Emery SL, et al. Intermittent and light daily smoking across racial/ethnic groups in the United States. Nicotine Tob Res. 2009;11:203-210.PubMedCrossRef

Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006;354:333-342.PubMedCrossRef

Fiore M, Jaen C, Baker T, et al. Treating Tobacco Use and Dependence Clinical Practice Guideline: 2008 Update. Washington, DC: U.S. Department of Health and Human Services; 2008.

Waldroup W, Gifford E, Kalra P. Adherence to smoking cessation treatment. In: Donohue W, Levensky E, eds. Promoting Treatment Adherence: A Practical Handbook for Health Care Providers. Thousand Oaks, CA: Sage; 2006:235-252.CrossRef

Catz SL, Jack LM, McClure JB, et al. Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine Tob Res. 2011;13:361-368.PubMedCrossRef

Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: Association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010;12:574-581.PubMedCrossRef

Shiffman S, Sweeney CT, Ferguson SG, Sembower MA, Gitchell JG. Relationship between adherence to daily nicotine patch use and treatment efficacy: Secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. Clin Ther. 2008;30:1852-1858.PubMedCrossRef

Akkaya A, Ozturk O, Cobanoglu H, et al. Evaluation of patients followed up in a cigarette cessation clinic. Respirology. 2006;11:311-316.PubMedCrossRef

10.

Dorner TE, Trostl A, Womastek I, Groman E. Predictors of short-term success in smoking cessation in relation to attendance at a smoking cessation program. Nicotine Tob Res. 2011;13:1068-1075.PubMedCrossRef

11.

Fucito LM, Toll BA, Salovey P, O'Malley SS. Beliefs and attitudes about bupropion: Implications for medication adherence and smoking cessation treatment. Psychol Addict Behav. 2009;23:373-379.PubMedCrossRef

12.

Okuyemi KS, Zheng H, Guo H, Ahluwalia JS. Predictors of adherence to nicotine gum and counseling among African-American light smokers. J Gen Intern Med. 2010;25:969-976.PubMedCrossRef

13.

Okuyemi KS, Harris KJ, Scheibmeir M, et al. Light smokers: Issues and recommendations. Nicotine Tob Res. 2002;4(Suppl 2):S103-S112.PubMedCrossRef

14.

Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: Three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331-342.PubMedCrossRef

15.

Cokkinides VE, Halpern MT, Barbeau EM, Ward E, Thun MJ. Racial and ethnic disparities in smoking-cessation interventions: Analysis of the 2005 National Health Interview Survey. Am J Prev Med. 2008;34:404-412.PubMedCrossRef

16.

Fu SS, Kodl MM, Joseph AM, et al. Racial/ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemiol Biomarkers Prev. 2008;17:1640-1647.PubMedCrossRef

17.

Ahluwalia JS, Okuyemi K, Nollen N, et al. The effects of nicotine gum and counseling among African American light smokers: A 2 × 2 factorial design. Addiction. 2006;101:883-891.PubMedCrossRef

18.

Cox LS, Nollen NL, Mayo MS, et al. Bupropion for smoking cessation in African American light smokers: A randomized controlled trial. J Natl Cancer Inst. 2012;104:290-298.PubMedCrossRef

19.

Fagan P, King G, Lawrence D, et al. Eliminating tobacco-related health disparities: Directions for future research. Am J Public Health. 2004;94:211-217.PubMedCrossRef

20.

Fisher JD, Fisher WA, Amico KR, Harman JJ. An information–motivation–behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25:462-473.PubMedCrossRef

21.

De-Navas-Walt C, Proctor B, Smith J. U.S. Census Bureau, Current Population Reports, P60-236. Income, poverty, and health insurance coverage in the United States: 2007. Washington, DC: U.S. Government Printing Office; 2008.

22.

Gallo LC, Matthews KA. Understanding the association between socioeconomic status and physical health: Do negative emotions play a role? Psychol Bull. 2003;129:10-51.PubMedCrossRef

23.

Adler NE, Ostrove JM. Socioeconomic status and health: What we know and what we don’t. Ann N Y Acad Sci. 1999;896:3-15.PubMedCrossRef

24.

Ryan KK, Garrett-Mayer E, Alberg AJ, Cartmell KB, Carpenter MJ. Predictors of cessation pharmacotherapy use among Black and non-Hispanic White smokers. Nicotine Tob Res. 2011;13:646-652.PubMedCrossRef

25.

Fu SS, Burgess D, van Ryn M, et al. Views on smoking cessation methods in ethnic minority communities: A qualitative investigation. Prev Med. 2007;44:235-240.PubMedCrossRef

26.

Nollen NL, Cox LS, Nazir N, et al. A pilot clinical trial of varenicline for smoking cessation in black smokers. Nicotine Tob Res. 2011;13:868-873.PubMedCrossRef

27.

Jacob P 3rd, Wilson M, Benowitz NL. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr. 1981;222:61-70.PubMed

28.

Benowitz N, Jacob P, Ahijevych K, et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4:149-159.CrossRef

29.

USDHHS: Behavioral Risk Factor Surveillance System (BRFSS). National Center for Chronic Disease Prevention and Promotion, Centers for Disease Control and Prevention, 2009.

30.

Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158:1789-1795.PubMedCrossRef

31.

Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5:74-79.PubMedCrossRef

32.

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.PubMedCrossRef

33.

Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult: Criterion validity of the 10-item Center for Epidemiological Studies Depression Scale (CES-D). Arch Intern Med. 1999;159:1701-1704.PubMedCrossRef

34.

Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol. 1988;54:1063-1070.PubMedCrossRef

35.

Carver C, White T. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment. J Pers Soc Psychol. 1994;67:319-333.CrossRef

36.

Mitchell SH. Measures of impulsivity in cigarette smokers and non-smokers. Psychopharmacology (Berlin). 1999;146:455-464.CrossRef

37.

Cohen S, Lichtenstein E. Perceived stress, quitting smoking, and smoking relapse. Health Psychol. 1990;9:466-478.PubMedCrossRef

38.

Resnicow K, Wallace D, Jackson A, et al. Dietary change through African-American churches: Baseline results and program description of the Eat for Life Trial. J Cancer Educ. 2000;15:156-163.PubMed

39.

Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289-294.PubMedCrossRef

40.

Cox LS, Tiffany ST, Christen AG. Evaluation of the brief Questionnaire of Smoking Urges (QSU—Brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3:7-16.PubMedCrossRef

41.

Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86:1119-1127.PubMedCrossRef

42.

Muscat JE, Stellman SD, Caraballo RS, Richie JP Jr. Time to first cigarette after waking predicts cotinine levels. Cancer Epidemiol Biomarkers Prev. 2009;18:3415-3420.PubMedCrossRef

43.

Program CTE: Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS, Washington, DC; 2006.

44.

Cohen S, Lichtenstein E, Mermelstein R, et al. Social support interventions for smoking cessation. In: Gottlieb B, ed. Marshalling Social Support: Format, Processes, and Effects. New York: Sage; 1998:211-240.

45.

Johnston AJ, Ascher J, Leadbetter R, et al. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs. 2002;62(Suppl 2):11-24.PubMedCrossRef

46.

Zhu AZ, Cox LS, Nollen N, et al. CYP2B6 and bupropion’s smoking-cessation pharmacology: The role of hydroxybupropion. Clin Pharmacol Ther. 2012;92:771-777.PubMedCrossRef

47.

Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;13:619-626.PubMedCrossRef

48.

Lerman C, Shields PG, Wileyto EP, et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics. 2002;12:627-634.PubMedCrossRef

49.

Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093-1108.PubMedCrossRef

50.

Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997;37:737-743.PubMedCrossRef

51.

Walsh RA. Over-the-counter nicotine replacement therapy: A methodological review of the evidence supporting its effectiveness. Drug Alcohol Rev. 2008;27:529-547.PubMedCrossRef

52.

Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: Data from the ITC Four-Country Survey. Nicotine Tob Res. 2011;13:94-102.PubMedCrossRef

53.

Fucito LM, Juliano LM. Effects of instructions on responses to the nicotine patch: A laboratory study. Psychopharmacology (Berlin). 2007;194:475-483.CrossRef

54.

Yerger VB, Wertz M, McGruder C, Froelicher ES, Malone RE. Nicotine replacement therapy: Perceptions of African-American smokers seeking to quit. J Natl Med Assoc. 2008;100:230-236.PubMed

55.

Lynam I, Catley D, Harris KJ, et al. African American smokers’ intention to use pharmacotherapy for cessation. Am J Health Behav. 2012;36:615-627.PubMedCrossRef

56.

Jacob P 3rd, Hatsukami D, Severson H, et al. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2002;11:1668-1673.PubMed

57.

Buchanan TS, Berg CJ, Cox LS, et al. Adherence to varenicline among African American smokers: An exploratory analysis comparing plasma concentration, pill count, and self-report. Nicotine Tob Res. 2012;19:1083-1091.CrossRef

58.

Thompson N, Nazir N, Cox LS, et al. Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial. Patient Prefer Adherence. 2011;5:475-482.PubMedCrossRef

Titel: Factors Associated with Discontinuation of Bupropion and Counseling Among African American Light Smokers in a Randomized Clinical Trial
verfasst von: Nicole L. Nollen, Ph.D.
Matthew S. Mayo, Ph.D.
Jasjit S. Ahluwalia, M.D., M.P.H., M.S.
Rachel F. Tyndale, Ph.D.
Neal L. Benowitz, M.D.
Babalola Faseru, M.D., M.P.H.
Taneisha S. Buchanan, Ph.D.
Lisa Sanderson Cox, Ph.D.
Publikationsdatum: 01.12.2013
Verlag: Springer US
Erschienen in: Annals of Behavioral Medicine / Ausgabe 3/2013
Print ISSN: 0883-6612
Elektronische ISSN: 1532-4796
DOI: https://doi.org/10.1007/s12160-013-9510-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Factors Associated with Discontinuation of Bupropion and Counseling Among African American Light Smokers in a Randomized Clinical Trial